Tegretol, also known by its active ingredient carbamazepine, is a medication used to treat seizures, nerve pain, and bipolar disorder. It may also be called Carbamazepine or Carbatrol. Tegretol helps control electrical activity in the brain to reduce seizures or pain.
Tegretol costs between £0.4 and £1.24 per pills. Depending on the size of the pack and the number of tablets inside (30 or 270 mg).
Tegretol, also known by its generic name carbamazepine, is primarily used as an anticonvulsant and mood-stabilizing drug. It’s administered for the treatment of various conditions including epilepsy, bipolar disorder, and trigeminal neuralgia. Tegretol works by reducing excessive electrical activity in the brain.
Tegretol’s active ingredient is carbamazepine. The molecular formula is C15H12N2O. It is structurally related to tricyclic antidepressants. Excipients may include maize starch, povidone, and magnesium stearate, among others.
Tegretol is available in various forms, including tablet, chewable tablet, and oral suspension. Dosage varies based on the condition being treated. For epilepsy, initial dosage for adults often starts at 200 mg twice daily, gradually increasing to an effective level. For bipolar disorder, the starting dose may be 200 mg daily, increasing as needed.
Tegretol is approved for management of epilepsy, specifically partial seizures with complex symptomatology, generalized tonic-clonic seizures, and mixed seizure patterns. It is also indicated for acute manic or mixed episodes associated with bipolar disorder, and for pain relief in trigeminal neuralgia.
Tegretol exhibits variable absorption, with peak plasma concentration occurring 4-8 hours post-administration. It undergoes hepatic metabolism, predominantly via the cytochrome P450 3A4 enzyme system. The half-life is between 12-65 hours depending on dosing regimen and duration of use.
Regular blood tests are recommended to monitor for potential adverse effects such as aplastic anemia and agranulocytosis. Liver function tests and renal function assessments should be periodically performed. Monitoring serum carbamazepine levels can help ensure therapeutic dosing.
Tegretol can interact with numerous medications. Co-administration with MAOIs is contraindicated. It can reduce the effectiveness of oral contraceptives, anticoagulants, and some antipsychotic drugs. Concomitant use with other antiepileptic drugs like phenytoin and phenobarbital can alter carbamazepine levels.
Contraindications for Tegretol include a history of bone marrow depression, hypersensitivity to carbamazepine or tricyclic compounds, and recent use of MAOIs. Patients with hepatic porphyrias should avoid this medication.
Common side effects include dizziness, drowsiness, ataxia, and nausea. Long-term use may lead to blurred vision, confusion, and behavioral changes. More severe reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis, and cardiac abnormalities.
Special caution is required when prescribing to pregnant or breastfeeding women due to potential teratogenic effects. Older adults may need dose adjustments due to an increased risk for side effects. Pediatric use is generally reserved for children over six years of age, with dosing carefully monitored.
Tegretol works by inhibiting sodium channels in neuronal membranes, thereby stabilizing hyperexcited nerve fibers. This mechanism helps to prevent seizure propagation and aids in mood stabilization. It also reduces synaptic transmission.
Store Tegretol at room temperature, away from moisture and heat. Ensure that the medication is kept out of reach of children. Dispose of unused or expired medication according to local guidelines.
Patients should be advised to take Tegretol regularly, at the same time each day, to maintain therapeutic levels. Abrupt discontinuation should be avoided to prevent withdrawal seizures. Alcohol consumption may exacerbate side effects and should be minimized.
Screening for HLA-B*1502 allele in patients of Asian descent can help mitigate the risk of severe skin reactions. Baseline and periodic CBCs, liver function tests, and renal function tests should be part of patient management while on Tegretol therapy.
Tegretol comes in various formulations including 200 mg immediate-release tablets, 100 mg and 400 mg extended-release tablets, and 100 mg/5 ml oral suspension. The choice of formulation often depends on patient-specific factors and condition being treated.
Tegretol’s inhibition of voltage-gated sodium channels decreases synaptic transmission and stabilizes neuronal membranes. This action blocks repetitive firing of neurons, which is central to its anticonvulsant and mood-stabilizing properties.
Before initiating Tegretol, comprehensive patient history should be taken to rule out contraindications. Detailed discussion on potential side effects and management strategies is crucial. Adjust initial doses for hepatic or renal impairment patients.